Ritlecitinib is a pyrrolopyrimidine compound that functions as a dual inhibitor of Janus kinase 3 and the TEC family of tyrosine kinases. It is an anti-inflammatory and immunosuppressive agent, used primarily for research and pharmaceutical manufacturing as an active pharmaceutical ingredient.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1792180-81-4
Ritlecitinib tosylate
pharmaceutical raw material
Daridorexant hydrochloride
pharmaceutical raw material
DL-magnesium lactate dihydrate
pharmaceutical raw material
Bortezomib
pharmaceutical raw material
Caspofungin acetate
pharmaceutical raw material
N-Methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
research compound
Tofacitinib
pharmaceutical raw material
N-Methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride
pharmaceutical raw material
1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
CBRJPFGIXUFMTM-WDEREUQCSA-N
C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3